Filter Your Search

  • ?
    Participants who either do not have cancer but are at high risk for developing the disease or have had cancer and are at high risk for developing a new cancer.
  • ?
    These trials look at ways to improve the quality of life of cancer patients, especially those who have side effects from cancer and its treatment. They find new ways to help people cope with pain, nutrition problems, infection, nausea and vomiting, sleep disorders, depression and other health problems.
  • open for enrollment

    Ph III Randomized Mk-3475In Muscle Invasive And Locally Advanced Urothelial Carcinoma Versus Observa

    Protocol: ALLIANCE-A031501

    Principal Investigator: Amir Mortazavi, MD

    Learn More
  • open for enrollment

    Daratumumab and Ibrutinib for Symptomatic, Treatment-Naïve CLL: A Phase 1b Proof-of-Concept Study

    Protocol: OSU-17143

    Principal Investigator: Jennifer A Woyach, MD

    Learn More
  • open for enrollment

    ph I/II trial of Venetoclax & BEAM conditioning followed by auto-SCT for pts w/ primary refrac NHL

    Protocol: OSU-17225

    Principal Investigator: Basem M William, MD

    Learn More
  • open for enrollment

    Ph III Tabelecleucel for Subjects w/ Epstein-Barr Virus- (ALLELE Study)

    Protocol: OSU-18035

    Principal Investigator: Robert A Baiocchi, MD, PhD

    Learn More
  • open for enrollment

    Ph2 Bruton's Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia

    Protocol: OSU-12200

    Principal Investigator: Kerry Rogers, MD

    Learn More
  • open for enrollment

    Radiation Therapy with or without Chemotherapy in Treating Patients with High-Risk Malignant Salivary Gland Tumors That Have Been Removed by Surgery

    Protocol: RTOG-1008


    Inclusion Criteria:

    Pathologically proven diagnosis of a malignant major salivary gland tumor or malignant minor salivary gland tumor of the head and neck of the following histologic subtypes:

    Intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma

    High-grade adenocarcinoma or high-grade mucoepidermoid carcinoma or salivary duct carcinoma

    High-grade acinic cell carcinoma or high-grade (> 30% solid component) adenoid cystic carcinoma

    Patients with diagnoses such as "undifferentiated or poorly differentiated carcinoma", "carcinoma-ex pleomorphic adenoma", "carcinoma not otherwise specified (NOS)" and others should be considered for this trial

    Surgical resection with curative intent within 8 weeks prior to registration

    Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (=< 1 mm) or microscopically positive surgical margin (American Joint Committee on Cancer [AJCC], 7th edition); patients must be free of distant metastases based upon the following minimum diagnostic workup:

    History/physical examination within 8 weeks prior to registration

    Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast computed tomography (CT) imaging of the chest is required; positron emission tomography (PET)/CT is acceptable

    Zubrod performance status 0-1

    Absolute neutrophil count (ANC) >= 1,800 cells/mm^3

    Platelets >= 100,000 cells/mm^3

    Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

    Serum creatinine < 2.0 mg/dl

    Total bilirubin < 2 x the institutional upper limit of normal (ULN)

    Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN

    Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential

    Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment

    All patients must have a Medical Oncology evaluation within 4 weeks prior to registration

    Patients must be deemed able to comply with the treatment plan and follow-up schedule

    Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for central review

    Exclusion Criteria:

    Patients with residual macroscopic disease after surgery

    Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)

    Prior systemic chemotherapy or radiation therapy for salivary gland malignancy; note that prior chemotherapy for a different cancer is allowable

    Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

    Severe, active co-morbidity, defined as follows:

    Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months

    Transmural myocardial infarction within the last 6 months

    Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

    Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

    Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, coagulation parameters are not required for entry into this protocol

    Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol

    Pre-existing >= grade 2 neuropathy

    Prior organ transplant

    Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

    Significant pre-existing hearing loss, as defined by the patient or treating physician

    Principal Investigator: Gregory A Otterson, MD

    Learn More
  • open for enrollment

    Transoral Robotic Surgery in Treating Patients with Benign or Malignant Tumors of the Head and Neck

    Protocol: OSU-07061


    Inclusion Criteria:

    Patient must present with indications for diagnostic or therapeutic approaches for benign and/or malignant diseases of the oral cavity or laryngopharynx (including the neoplastic lesions of the tongue, tongue base, retromolar trigone, tonsils, palate, posterior and lateral pharynx, glottic, supraglottic and subglottic larynx)

    Patients must have adequate transoral exposure of the oral cavity and laryngopharynx for TORS instrumentation; for the non-surgical arm: Patients planned to receive non-surgical treatment (e.g., chemo and/or radiation); the 7 surgical (TORS) arms include: tonsil cancer: T1, tonsil cancer: T2, base of tongue cancer: T1, base of tongue cancer: T2, supraglottic cancer, unknown primary cancer, and other tumors; the 3 non-surgical arms are: tonsil cancer, base of tongue cancer, and supraglottic/hypopharyngeal/other cancers

    Written informed consent and/or Consent waiver by institutional review board (IRB)

    Exclusion Criteria:

    Unexplained fever and/or untreated, active infection

    Patient pregnancy

    Previous head and neck surgery that would preclude transoral/robotic procedures; this is at the investigator’s discretion; this is not an exclusion criterion for the non-surgical arm

    The presence of medical conditions contraindicating general anesthesia or transoral surgical approaches; this is not an exclusion criterion for the non-surgical arm

    Inability to grant informed consent


    Inability to adequately visualize anatomy to perform the diagnostic or therapeutic surgical approach transorally

    Learn More